NEU neuren pharmaceuticals limited

Ann: Update - Notification of buy-back - NEU, page-50

  1. 1,573 Posts.
    lightbulb Created with Sketch. 187
    What about the acquisition of a marketing and distribution company?

    In an interview following the third Phase 2 result, the topic of acquisition was raised by the interviewer. I think it’s in the context of additions to the drug pipeline, but why not bolt on a sales and marketing division and retain all the value of NNZ-2591?

    Timestamp: 23:30
    On the Couch with Jon Pilcher: What’s Next for Neuren Pharma

    A search on Grok suggests there are a few options that could be "affordable" (less than $1B). With successful Phase 3 approvals, we should be worth US$7–10B, so it could be a good investment.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.96
Change
-0.140(1.07%)
Mkt cap ! $1.612B
Open High Low Value Volume
$13.20 $13.36 $12.82 $4.627M 354.8K

Buyers (Bids)

No. Vol. Price($)
1 7585 $12.96
 

Sellers (Offers)

Price($) Vol. No.
$13.03 3344 2
View Market Depth
Last trade - 16.10pm 16/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.